[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Second Affiliated Hospital of Zunyi Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":74},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100635927","phase-2-induction-chemo-immunotherapy--radiotherapy-vs-concurrent-chemoradiotherapy-for-unresectable-locally-advanced-esophageal-squamous-cell-carcinoma-100635927",false,"NCT07559045","Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma","Efficacy and Safety of Induction Chemo-Immunotherapy Followed by Radiotherapy vs Concurrent Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized, Two-Arm, Phase II Study","Inclusion Criteria:\n\n* Histologically or cytologically confirmed unresectable stage III-IVA esophageal squamous cell carcinoma (ESCC)\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Adequate organ function (bone marrow, liver, renal, cardiac) within 2 weeks prior to randomization\n* Measurable or evaluable disease per RECIST 1.1\n* Willing to provide written informed consent\n\nExclusion Criteria:\n\n* Previous radiotherapy to the chest or previous systemic chemotherapy for ESCC\n* History of other malignancies within the last 5 years (except cured basal cell carcinoma or cervical carcinoma in situ)\n* Severe comorbidities (uncontrolled hypertension, NYHA class III-IV heart failure, active infection, etc.)\n* Known hypersensitivity to any study drugs (paclitaxel, cisplatin\u002Fcarboplatin, PD-1 antibody)\n* Pregnant or lactating women\n* Participation in another clinical trial within 30 days prior to randomization","ALL","18 Years","75 Years",{"count":20,"type":21},92,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a prospective, randomized, phase II clinical study in patients with unresectable stage III-IVA esophageal squamous cell carcinoma (ESCC). Eligible patients will be randomly assigned in a 1:1 ratio to two treatment groups. The experimental group will receive 3 cycles of induction therapy with PD-1 antibody plus chemotherapy, followed by radiotherapy, and then maintenance therapy with PD-1 antibody monotherapy. The control group will receive concurrent chemoradiotherapy, followed by maintenance therapy with PD-1 antibody monotherapy. The primary endpoints are the complete response (CR) rate at 3 months after radiotherapy (assessed by investigators) and the 1-year progression-free survival (PFS) rate. Secondary endpoints include overall survival (OS), progression-free survival (PFS), duration of response, objective response rate (ORR), local-regional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), quality of life, and safety profile.",[27],"Esophageal Squamous Cell Carcinoma (ESCC)",[29,30,31,32,33],"Esophageal Squamous Cell Carcinoma","Chemo-Immunotherapy","Induction Therapy","Concurrent Chemoradiotherapy","PD-1 Inhibitor","RECRUITING","2026-04-26",{"date":37,"type":38},"2026-04-30","ACTUAL",{"date":40,"type":38},"2026-01-01",{"date":42,"type":21},"2028-06-30",{"name":44,"class":45},"Second Affiliated Hospital of Zunyi Medical University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100571820","machine-learning-for-predicting-and-managing-quality-of-life-in-lung-cancer-immunotherapy-patients-100571820","NCT06725225","Machine Learning for Predicting and Managing Quality of Life in Lung Cancer Immunotherapy Patients","Development of a Machine Learning-Based Risk Prediction Model and Stratified Management Strategies for Quality of Life in Lung Cancer Patients Undergoing Immunotherapy","Inclusion Criteria:\n\n1. Histologically diagnosed with lung cancer\n2. Age over 18 years\n3. Currently receiving immunotherapy for lung cancer\n4. Good verbal communication ability\n5. Informed consent signed by the patient or family member\n\nExclusion Criteria:\n\n1. Cognitive impairment or mental illness\n2. Other severe diseases",{"count":55,"type":21},200,[57],"NA","The goal of this study is to explore whether health-related quality of life (HRQoL) can be used as a predictive indicator for lung cancer patients and to implement clinical interventions. The study addresses two main objectives:\n\nAnalyzing HRQoL data of lung cancer patients undergoing immunotherapy using machine learning clustering methods to explore data patterns and build an HRQoL early warning model (already developed).\n\nValidating this HRQoL early warning model in real-world settings by classifying patients with different HRQoL characteristics and assessing the clinical value of the model",[60],"Lung Cancer Patients",[62,63,64],"HRQOL","lung cancer","immunotherapy","NOT_YET_RECRUITING","2024-12-09",{"date":68,"type":38},"2024-12-13",{"date":70,"type":21},"2025-01-01",{"date":72,"type":21},"2026-04-01",{"name":44,"class":45},""]